Cardiologists Endorse Weight-Loss Drugs, But Holistic Approach Remains Key
Table of Contents
A recent endorsement of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy), by teh American College of Cardiology (ACC) as a first-line therapy for weight management signals a major shift in cardiometabolic care. The decision reflects growing evidence of these drugs’ efficacy in achieving notable weight loss and reducing cardiovascular risk,even for individuals without diabetes. However, experts caution that the increasing reliance on pharmacological interventions must not overshadow the foundational role of lifestyle changes.
A Paradigm Shift in Obesity Treatment
For decades, the cornerstone of managing obesity and its associated health risks has been behavioral and lifestyle modifications – including nutritional improvements, increased physical activity, and patient education.pharmacologic interventions where traditionally reserved for those who did not respond adequately to these methods. Now, the ACC’s guidance suggests a more proactive role for medications like semaglutide, representing a significant evolution in clinical practice.
“This undoubtedly transforms our therapeutic landscape,” one analyst noted.
How GLP-1 Receptor Agonists Work
GLP-1 receptor agonists, such as semaglutide, work by increasing insulin secretion and suppressing glucagon release, leading to improved blood glucose control. They also promote weight loss by delaying gastric emptying and decreasing appetite. A meta-analysis by Moiz et al. demonstrated significant weight reduction with semaglutide use, showing a long-term relative decrease of 12.1% (95% CI,-13.5% to -10.7%) and an absolute decrease of 12.3 kg (95% CI, -13.6 to -11.0) in patients without diabetes.
Reference: Moiz, H., et al.GLP-1 receptor agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127. doi:10.1016/j.obpill.2024.100127
Balancing Benefits with Potential Risks
While offering significant benefits, GLP-1 receptor agonists are not without potential side effects. Common adverse effects are primarily gastrointestinal, including nausea, diarrhea, constipation, and vomiting. More serious, though less frequent, risks include gallbladder disorders and acute pancreatitis.Emerging concerns also point to increased aspiration risk during anesthesia and difficulties with bowel planning for procedures like colonoscopies due to delayed gastric emptying.
The widespread availability of compounded versions and access through medical spas also raises concerns about misuse, particularly among individuals with body dysmorphia or eating disorders.In these cases, a senior official stated, consultation with both an eating disorder specialist and a medical provider is crucial before initiating therapy. Compounded formulations, frequently enough containing additional ingredients like vitamin B12 and nicotinamide adenine dinucleotide, shoudl be treated as regulated substances.
Reference: FDA’s new GLP-1 compounding guidelines: what clinical research reveals. Medical & Clinical Research.March 19, 2025. Accessed October 31, 2025. https://medclinres.org/fdas-new-glp-1-compounding-guidelines-what-clinical-research-reveals/
the Need for Complete, Patient-Centered Care
As the use of GLP-1 therapies expands, a pressing need for long-term safety data emerges. Supervised community-based clinical trials are needed to understand drug interactions, adverse effects, and complications. Furthermore, healthcare systems must
